Gary Mccort

This inventor holds 19 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Syntex Pharmaceuticals, Ltd., Sanofi-Aventis. Active years: 1994-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gary Mccort. Retrieved from https://idiyas.com/inventor/gary-mccort

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 11)

% Patents Active = 73.7

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 4.7

ph-index = 9

Forward Citations = 174(Granted Patents)

Company Filing History:

Syntex Pharmaceuticals, Ltd.

Years Active: 1994-2022

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Therapeutic Uses

Cardiovascular Diseases

Pyridino-Pyridinone

Cyclic Azaindoles

Serotonin Antagonists

Imidazole Derivatives

Benzo[7]annulene

Alkynyl-Naphthyridones

CaMKII Kinase Inhibitors

Pharmaceutical Preparations

Pyridino-Pyrimidine

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11214541 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2022-01-04),

2. 11149031 - Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof (2021-10-19),

3. 10570090 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2020-02-25),

4. 9714221 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2017-07-25),

5. 8975250 - 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases (2015-03-10),

6. 8912224 - Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals (2014-12-16),

7. 8623893 - Pyridino-pyridinone derivatives, preparation and therapeutic use thereof (2014-01-07),

8. 8586602 - Derivatives of 7 alkynyl-1,8 naphthyridones, preparation method thereof and use of same in therapeutics (2013-11-19),

9. 8580813 - Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals (2013-11-12),

10. 8470847 - Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics (2013-06-25),

11. 8436011 - Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof (2013-05-07),

12. 8415336 - Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals (2013-04-09),

13. 8263614 - Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics (2012-09-11),

14. 8211885 - Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals (2012-07-03),

15. 5958924 - Quinolein-2 (1H)-one derivatives as serotonin antagonists (1999-09-28),

Title: Gary McCort - Innovative Inventor from Paris

Introduction: Gary McCort is a renowned inventor based in Paris, France, known for his groundbreaking contributions to various industries.

Latest Patents: Gary McCort holds several patents in the fields of technology, healthcare, and sustainable energy, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Gary McCort has worked with leading research institutions and universities to develop cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, Gary McCort has collaborated with top companies, inventors, and patent attorneys to bring his inventions to life, fostering a culture of innovation and creativity.

Conclusion: Gary McCort's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs worldwide.

Profile summary based on public USPTO records.